Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease
Article first published online: 16 JUL 2013
© 2013 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Veterinary and Comparative Oncology
How to Cite
Selting, K. A., Sharp, C. R., Ringold, R. and Knouse, J. (2013), Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease. Veterinary and Comparative Oncology. doi: 10.1111/vco.12052
- Article first published online: 16 JUL 2013
- Manuscript Accepted: 7 JUN 2013
- Manuscript Revised: 3 JUN 2013
- Manuscript Received: 22 DEC 2012
- Veterinary Diagnostics Institute, Inc
- 3Editorial: serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. Journal of Veterinary Internal Medicine 2004; 18: 595–596..
- 5Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity - evaluation of a new, fully automated non-radiometric assay. International Journal of Oncology 2009; 34: 505–510., , , , and .
- 11Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Veterinary Journal 2007; 188: 192., and .
- 26Jasensky JK, Hennies M, Kohn B, Einspanier R. Development of an Enzyme-linked immunosorbent assay (ELISA) for the measurement of canine C-reactive protein. Poster and abstract, InnLab Conference 2012, Gottingen, Germany, February 2–3, 2012.